Market Overview –

The Middle East and Africa Human Vaccines Market focuses on the development, production, and distribution of vaccines to prevent infectious diseases in the Middle East and Africa regions. Vaccines play a crucial role in public health by preventing the spread of communicable diseases such as influenza, measles, hepatitis, and COVID-19.

In recent years, the human vaccines market in the Middle East and Africa has witnessed significant growth due to several factors. Firstly, there has been increasing government initiatives and vaccination campaigns aimed at expanding immunization coverage and controlling infectious disease outbreaks. Key players in this market include pharmaceutical companies, vaccine manufacturers, healthcare providers, and government agencies, collaborating to develop and deliver vaccines to the population.

Moreover, advancements in vaccine technology, including the development of new vaccine platforms, adjuvants, and delivery systems, have led to the introduction of more effective and safer vaccines. These advancements enable the production of vaccines against emerging infectious diseases and vaccine-preventable diseases that are endemic to the region.

The human vaccines market is dynamic, with a significant focus on the papillomavirus vaccine. As awareness of HPV-related diseases, including cervical cancer, increases, demand for vaccination against the virus rises. Pharmaceutical companies are actively developing and promoting HPV vaccines, contributing to market growth and the prevention of HPV-related illnesses worldwide.

In 2022, the market for human vaccinations in the Middle East and Africa was estimated to be worth USD 0.6 billion. The market for human vaccines is expected to expand at a compound annual growth rate (CAGR) of 5.7% between 2023 and 2032, from USD 0.63 billion in 2023 to USD 1.03 billion.

The MEA Human Vaccines Market   - Segmentation

The report is segmented into seven key dynamics;

By Technology: Attenuated, Inactivated, Toxoid, Conjugate, & Subunit, Recombinant DNA, and others.

By Disease Indication: Influenza, Pneumococcal, Hepatitis, Rotavirus, DTP, Polio, and others.

By Type : Prophylactic, Therapeutic, and others.

By Composition: Mono Vaccine and Combination Vaccines.

By End-user: Children and Adults.

By Route of Administration: Oral, Injectables, and others.

By Regions:  Israel, Turkey, GCC, and the rest-of-the-Middle-East and Countries in the African region.

The MEA Human Vaccines Market - Country-wise Analysis

The MEA human vaccines market is emerging as a lucrative market, growing overall. The United Arab Emirates (UAE) holds for the largest share in the MEA human vaccines market, followed by Egypt. On the other hand, Sub Saharan regions of Africa, account for the fastest-growing market, followed by the-rest-of-the-African market, due to the huge unmet medical needs. Also, increasing per capita healthcare expenditures and the rising R&D funds invested for the new vaccine development act as major tailwinds for the market growth, especially in the Middle Eastern regions.

Key Players –

Human Vaccines companies include GlaxoSmithKline Plc., Merck & Co. Inc., Pfizer Inc., Sanofi Pasteur Inc., AstraZeneca Plc., Bharat Biotech, Shenzhen Kangtai Biological Products, Valeant Pharmaceuticals, Emergent Biosolutions Inc., Astellas Pharma Inc., and Panacea Biotec.

Related Reports –

cancer diagnostics market

medical imaging market

home healthcare market

orphan drugs market

For more information visit at MarketResearchFuture